发布求助
文献互助 智能选刊 最新文献

Drug Discovery Today最新文献

筛选
英文 中文
Enhancing clinical trial outcome prediction with artificial intelligence: a systematic review
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-15 DOI: 10.1016/j.drudis.2025.104332
Long Qian , Xin Lu , Parvez Haris , Jianyong Zhu , Shuo Li , Yingjie Yang
{"title":"Enhancing clinical trial outcome prediction with artificial intelligence: a systematic review","authors":"Long Qian ,&nbsp;Xin Lu ,&nbsp;Parvez Haris ,&nbsp;Jianyong Zhu ,&nbsp;Shuo Li ,&nbsp;Yingjie Yang","doi":"10.1016/j.drudis.2025.104332","DOIUrl":"10.1016/j.drudis.2025.104332","url":null,"abstract":"<div><div>Clinical trials are pivotal in drug development yet fraught with uncertainties and resource-intensive demands. The application of AI models to forecast trial outcomes could mitigate failures and expedite the drug discovery process. This review discusses AI methodologies that impact clinical trial outcomes, focusing on clinical text embedding, trial multimodal learning, and prediction techniques, while addressing practical challenges and opportunities.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104332"},"PeriodicalIF":6.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to "Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)" [Drug Discov. Today 30(2) (2025) 104291].
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-15 DOI: 10.1016/j.drudis.2025.104326
Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl
{"title":"Corrigendum to \"Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)\" [Drug Discov. Today 30(2) (2025) 104291].","authors":"Alexander Schuhmacher, Markus Hinder, Elazar Brief, Oliver Gassmann, Dominik Hartl","doi":"10.1016/j.drudis.2025.104326","DOIUrl":"10.1016/j.drudis.2025.104326","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":" ","pages":"104326"},"PeriodicalIF":6.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2024 in Review: FDA Approval of New Medicines
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-15 DOI: 10.1016/j.drudis.2025.104334
Michael S. Kinch, Zachary Kraft, Tyler Schwartz
{"title":"2024 in Review: FDA Approval of New Medicines","authors":"Michael S. Kinch,&nbsp;Zachary Kraft,&nbsp;Tyler Schwartz","doi":"10.1016/j.drudis.2025.104334","DOIUrl":"10.1016/j.drudis.2025.104334","url":null,"abstract":"","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104334"},"PeriodicalIF":6.5,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-13 DOI: 10.1016/j.drudis.2025.104331
Katarzyna Regulska , Paulina Gieremek , Marcin Michalak , Tomasz Kolenda , Marlena Janiczek-Polewska , Joanna Kozłowska-Masłoń , Zefiryn Cybulski , Beata J. Stanisz
{"title":"Ramipril, perindopril and trandolapril as potential chemosensitizers in ovarian cancer: Considerations for drug repurposing","authors":"Katarzyna Regulska ,&nbsp;Paulina Gieremek ,&nbsp;Marcin Michalak ,&nbsp;Tomasz Kolenda ,&nbsp;Marlena Janiczek-Polewska ,&nbsp;Joanna Kozłowska-Masłoń ,&nbsp;Zefiryn Cybulski ,&nbsp;Beata J. Stanisz","doi":"10.1016/j.drudis.2025.104331","DOIUrl":"10.1016/j.drudis.2025.104331","url":null,"abstract":"<div><div>Ovarian cancer (OC) has poor survival statistics and increasing prevalence. One of the new options for its therapy could be overcoming platinum resistance. In this review, we have considered the idea of repositioning angiotensin-converting enzyme inhibitors (ACE-Is) as chemosensitizers. These drugs have been shown to suppress angiogenesis and OC cell migration in preclinical studies. Moreover, clinical data have shown that using ACE-Is with standard chemotherapy prolongs patient survival. Based on this rationale, we discuss the available <em>in vitro</em> models of OC for future studies with ACE-Is and demonstrate an <em>in silico</em> approach that has enabled us to select the most promising molecules: perindopril, ramipril, trandolapril and their diketopiperazine derivatives.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104331"},"PeriodicalIF":6.5,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dissolving microneedles for brain delivery: Recent advances and challenges
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-12 DOI: 10.1016/j.drudis.2025.104330
Kaustubh Ajit Kolekar , Popat S. Kumbhar , Sukriti Vishwas , Kamal Dua , Sachin Kumar Singh
{"title":"Dissolving microneedles for brain delivery: Recent advances and challenges","authors":"Kaustubh Ajit Kolekar ,&nbsp;Popat S. Kumbhar ,&nbsp;Sukriti Vishwas ,&nbsp;Kamal Dua ,&nbsp;Sachin Kumar Singh","doi":"10.1016/j.drudis.2025.104330","DOIUrl":"10.1016/j.drudis.2025.104330","url":null,"abstract":"<div><div>Over the past decade, dissolving microneedles (DMNs) have emerged as a promising approach for drug delivery to the brain. They are tiny devices designed to penetrate biological barriers, offering a painless method for localized and controlled drug delivery. They are suitable for delivering drugs that are susceptible to degradation when delivered orally. Recently, drug-loaded DMNs have been explored for treating neurodegenerative diseases, including Alzheimer’s (AD) and Parkinson’s disease (PD). DMNs can deliver drugs efficiently to the brain via the intranasal, transdermal, and intracranial routes. In this review, we discuss the use of DMNs for delivering drugs to the brain, recent technological advances, clinical status, and current challenges related to their translation.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104330"},"PeriodicalIF":6.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment 制药公司对目前在非临床安全性评估中使用新方法的机遇和见解。
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-12 DOI: 10.1016/j.drudis.2025.104328
Jacintha Shenton , Imein Bousnina , Michael Oropallo , Rhiannon David , Lucinda Weir , Thomas K. Baker , Helen-Marie Dunmore , Remi Villenave , Mary McElroy , Betty Pettersen , Tushar Kokate , Claudette L. Fuller , Kimberly A. Homan , Eloise Hudry , Charles Wood , Sam Gunter
{"title":"Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment","authors":"Jacintha Shenton ,&nbsp;Imein Bousnina ,&nbsp;Michael Oropallo ,&nbsp;Rhiannon David ,&nbsp;Lucinda Weir ,&nbsp;Thomas K. Baker ,&nbsp;Helen-Marie Dunmore ,&nbsp;Remi Villenave ,&nbsp;Mary McElroy ,&nbsp;Betty Pettersen ,&nbsp;Tushar Kokate ,&nbsp;Claudette L. Fuller ,&nbsp;Kimberly A. Homan ,&nbsp;Eloise Hudry ,&nbsp;Charles Wood ,&nbsp;Sam Gunter","doi":"10.1016/j.drudis.2025.104328","DOIUrl":"10.1016/j.drudis.2025.104328","url":null,"abstract":"<div><div>Sharing New Approach Methodology (NAM)-based regulatory experiences is crucial for improving human risk assessment and reducing animal use in drug safety testing. To foster broader adoption, the Biotechnology Innovation Organization surveyed companies about NAM usage and collected case studies showcasing NAM-based regulatory filings for biotherapeutics, where NAMs replaced large animal studies for safety assessment. These scientifically justified approaches were generally accepted by global health authorities, particularly in the context of species relevance limitations, prior target modulation experience, and/or when addressing severe disease. Despite successes with NAM-based global regulatory filings, there are concerns from companies about global regulatory harmonization and clinical translatability. NAMs have the potential for greater uptake with enhanced guidance and industry–regulatory agency collaboration being key to their adoption.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104328"},"PeriodicalIF":6.5,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143629997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecule-rich solutions for achieving novel non-opioid analgesics
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-11 DOI: 10.1016/j.drudis.2025.104329
Xingxing Liu , Chaoyi Deng , Yu Deng , Xudong Luo , Wensheng Zhang
{"title":"Molecule-rich solutions for achieving novel non-opioid analgesics","authors":"Xingxing Liu ,&nbsp;Chaoyi Deng ,&nbsp;Yu Deng ,&nbsp;Xudong Luo ,&nbsp;Wensheng Zhang","doi":"10.1016/j.drudis.2025.104329","DOIUrl":"10.1016/j.drudis.2025.104329","url":null,"abstract":"<div><div>Despite their efficacy, opioids have long been associated with risks of addiction, tolerance, and dependence, leaving an unmet clinical need for pain treatment. Efforts have been devoted to developing novel classes of pain-relieving medication that outperform current options in terms of pain relief, side-effect profiles, and potential for abuse, but with limited success. Recent advances in the neurobiology of pain have shed light on the potential of targeting non-opioid receptors involved in pain processing. In this review, we identify avenues, ranging from molecular-based approaches to molecule-rich solutions, for effectively identifying non-opioid analgesics free from the side effects associated with opioids.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104329"},"PeriodicalIF":6.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging machine learning for drug repurposing in rheumatoid arthritis
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-11 DOI: 10.1016/j.drudis.2025.104327
Qin-Yi Su , Yi-Xin Cao , He-Yi Zhang , Yong-Zhi Li , Sheng-Xiao Zhang
{"title":"Leveraging machine learning for drug repurposing in rheumatoid arthritis","authors":"Qin-Yi Su ,&nbsp;Yi-Xin Cao ,&nbsp;He-Yi Zhang ,&nbsp;Yong-Zhi Li ,&nbsp;Sheng-Xiao Zhang","doi":"10.1016/j.drudis.2025.104327","DOIUrl":"10.1016/j.drudis.2025.104327","url":null,"abstract":"<div><div>Rheumatoid arthritis (RA) presents a significant challenge in clinical management because of the dearth of effective drugs despite advances in understanding its mechanisms. Drug repurposing has emerged as a promising strategy to address this gap, offering potential cost savings and expediting drug discovery. Notably, computational methods, particularly machine learning (ML), have shown promise in RA drug repurposing. In this review, we survey various drug-repurposing approaches, both classical and contemporary, highlighting the pivotal role of ML. We summarize RA candidate drugs identified through computational strategies and discuss prevailing challenges in this domain. Leveraging ML, alongside a deepening understanding of RA mechanisms, holds promise for enhancing pharmacological treatment options for patients with RA.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 4","pages":"Article 104327"},"PeriodicalIF":6.5,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enabling research and development innovation in the life sciences: A case study
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-01 DOI: 10.1016/j.drudis.2025.104325
Mahmoud M. Ibrahim , Karen Köhler , Monika Lessl , Michael Gamalinda
{"title":"Enabling research and development innovation in the life sciences: A case study","authors":"Mahmoud M. Ibrahim ,&nbsp;Karen Köhler ,&nbsp;Monika Lessl ,&nbsp;Michael Gamalinda","doi":"10.1016/j.drudis.2025.104325","DOIUrl":"10.1016/j.drudis.2025.104325","url":null,"abstract":"<div><div>Many industries face challenges in driving an innovation strategy that sustains value growth and aligns with the company’s social responsibility. Bayer is in a unique position as a global diversified life science company, with a mission to alleviate hunger and improve health. We propose that research-intensive firms such as Bayer must consider an R&amp;D innovation strategy in addition to a typical product innovation strategy to ensure successful short- and long-term R&amp;D-enabled value creation. To this end, we introduce an R&amp;D technology–product–market innovation framework and apply this framework to a case study involving the Life Science Collaboration (LSC) program, Bayer’s internal multidisciplinary R&amp;D seed fund. In the light of the innovation framework we propose, we show that the LSC’s community-driven decision-making enables broad strategic alignment with business needs while maintaining space for out-of-the-box ideas.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 3","pages":"Article 104325"},"PeriodicalIF":6.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143583963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Embracing the future of medicine with virtual patients
IF 6.5 2区 医学
Drug Discovery Today Pub Date : 2025-03-01 DOI: 10.1016/j.drudis.2025.104322
Ken Wang , Neil John Parrott , Thierry Lavé
{"title":"Embracing the future of medicine with virtual patients","authors":"Ken Wang ,&nbsp;Neil John Parrott ,&nbsp;Thierry Lavé","doi":"10.1016/j.drudis.2025.104322","DOIUrl":"10.1016/j.drudis.2025.104322","url":null,"abstract":"<div><div>The adoption of virtual patients promises to revolutionize pharmaceutical R&amp;D and health care through more patient-centric approaches and is driven by integrating innovations in computational approaches, AI, and advanced <em>in vitro</em> human model systems. Virtual patients can create the conditions for faster and more predictive R&amp;D, affecting all drivers of R&amp;D productivity. Virtual patients enable personalized health care, ensuring precise drug dosing and scheduling to maximize efficacy and minimize adverse effects. Numerous concrete examples demonstrate the transformative potential of virtual patients in real-world scenarios, showcasing significant improvements in drug development and clinical outcomes. Despite challenges in data variability, regulatory compliance, and data privacy, virtual patients hold immense potential to transform R&amp;D and clinical practices, driving a new era of personalized and efficient R&amp;D and health care.</div></div>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":"30 3","pages":"Article 104322"},"PeriodicalIF":6.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143539644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信